These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21601377)

  • 1. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.
    Hattangadi-Gluth JA; Wo JY; Nguyen PL; Abi Raad RF; Sreedhara M; Niemierko A; Freer PE; Georgian-Smith D; Bellon JR; Wong JS; Smith BL; Harris JR; Taghian AG
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1185-91. PubMed ID: 21601377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.
    Jia H; Jia W; Yang Y; Li S; Feng H; Liu J; Rao N; Jin L; Wu J; Gu R; Zhu L; Chen K; Deng H; Zeng Y; Liu Q; Song E; Su F
    World J Surg Oncol; 2014 Sep; 12():289. PubMed ID: 25241216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second invasive breast cancers in patients treated with breast-conserving therapy.
    Wang J; Tang H; Yin K; Li X; Xie X; Hughes KS
    Eur J Surg Oncol; 2021 Oct; 47(10):2492-2498. PubMed ID: 34134902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation.
    Wilkinson JB; Shah C; Amin M; Nadeau L; Shaitelman SF; Chen PY; Grills IS; Martinez AA; Mitchell CK; Wallace MF; Vicini FA
    Clin Breast Cancer; 2017 Feb; 17(1):55-60. PubMed ID: 27666436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy.
    Wong FY; Chin FK; Lee KA; Soong YL; Chua ET
    Ann Acad Med Singap; 2011 Feb; 40(2):90-6. PubMed ID: 21468463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.
    Arvold ND; Taghian AG; Niemierko A; Abi Raad RF; Sreedhara M; Nguyen PL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2011 Oct; 29(29):3885-91. PubMed ID: 21900114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
    Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
    Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
    Ling DC; Sutera PA; Iarrobino NA; Diego EJ; Soran A; Johnson RR; Bhargava R; Champ CE; Beriwal S
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):869-876. PubMed ID: 30885777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.